Intermittent Boluses Versus Infusion of Propofol During Gastroscopy - Trial NCT06378879
Access comprehensive clinical trial information for NCT06378879 through Pure Global AI's free database. This phase not specified trial is sponsored by Al-Balqa Applied University and is currently Not yet recruiting. The study focuses on Anesthesia. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Al-Balqa Applied University
Timeline & Enrollment
N/A
May 06, 2024
Jul 30, 2025
Primary Outcome
Sedation induction time (minutes),Total dose of propofol (mg),Recovery time (minutes)
Summary
It is unclear whether continuous infusion or intermittent bolus injection of propofol is
 better for achieving adequate sedation during a standard upper endoscopy. The study aimed to
 compare the efficacy and safety of continuous infusion and intermittent bolus injection of
 Propofol (Diprivan) during a standard upper endoscopy. In this prospective study, patients
 will be randomly assigned to undergo a standard upper endoscopy with either continuous
 infusion (CI group) or intermittent bolus injection (BI group) of Propofol (Diprivan)
 administered by an anesthesiologist. The primary outcome will be to assess the quality of
 sedation by the endoscopist (VAS). In addition to other sedation-related parameters that will
 include sedation induction time (minutes), total dose of propofol (mg), recovery time
 (minutes) using Aldrete score, any involuntary patient movement, and adverse events.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06378879
Non-Device Trial